How to Apply to JLABS by Johnson & Johnson in 2026
JLABS is lab space and access, not an investment program. Johnson & Johnson publishes no equity stake, no residency deadline and no acceptance rate.
How to Apply to JLABS by Johnson & Johnson in 2026
To apply to JLABS by Johnson & Johnson, choose your model (physical residency or virtual membership), review the strategic areas of focus, prepare a non-confidential application, then submit it through the portal (JLABS). JLABS publishes no residency deadline, no acceptance rate and no equity stake.
How to apply to JLABS by Johnson & Johnson starts with a category correction: this is lab space and access, not an investment program. The official residency page lists lab space, equipment, collaborative offices, industry connections, mentorship and funding opportunities, and it does not promise a grant or investment amount for ordinary residency (JLABS).
The second correction is the one founders lose sleep over. JLABS describes its model as no-strings-attached, letting entrepreneurs develop their science while retaining their intellectual property, and the official material does not state that JLABS takes equity (JLABS).
How to apply to JLABS by Johnson & Johnson in 2026: the seven steps
- Choose the model first. JLABS offers physical residency for companies that need lab or office space, and virtual membership for startups that do not (JLABS).
- Pick the site, not just the brand. Incubation and acceleration runs through 11 locations globally and virtually, and physical and virtual availability differs by site (JLABS).
- Read the strategic areas of focus before you write a word. The published sequence is choose the model, review the strategic areas of focus, prepare the application, then submit through the portal (JLABS).
- Assemble non-confidential material only. The resident application asks for the science or technology, license or IP coverage, customers or beneficiaries, competitive differentiation, team biographies, a 12 to 18 month project and milestone plan, and funding sources or partnerships (JLABS).
- Fill the company fields with the specifics the form names: company information, therapeutic area, differentiation, milestones, publications, IP status, financial information such as funding rounds and partnerships, and footprint requirements for physical residency (JLABS).
- Answer the solvency question head on. The resident screen seeks transformational science or technology, a significant unmet medical or market need, a strong team, financial solvency, and alignment with Johnson & Johnson strategic interests or adjacencies (JLABS).
- Submit through the application portal and plan around committee review rather than a same week answer (JLABS).
JLABS by Johnson & Johnson equity terms: no equity, and no published price
The equity question has a short answer: the official material does not state that JLABS takes equity, and it describes the model as no-strings-attached, allowing entrepreneurs to develop their science while retaining their intellectual property (JLABS). Source that to the program's own page in your diligence, not to a third-party summary.
No equity is not the same as no cost. Residency is a lab and office arrangement, so footprint is a budget line, and footprint requirements are a field you complete on the application itself (JLABS). The official pages do not publish a rate card, so get current fees and minimum term in writing from the specific site before you plan a move.
Access is not a deal. The published material describes funding opportunities and connections rather than guaranteeing investment, partnership, licensing or an acquisition by Johnson & Johnson (JLABS). Build your plan as though no Johnson & Johnson transaction ever happens, because none is promised.
What the JLABS by Johnson & Johnson application actually asks for
The form reads like a diligence pack, not a pitch deck.
| Field group | What to put in it |
|---|---|
| Science | The transformational claim, stated non-confidentially |
| IP | License or IP coverage and current status |
| Market | Therapeutic area, customers or beneficiaries, competitive differentiation |
| Team | Biographies that show the science has an owner |
| Plan | A 12 to 18 month project and milestone plan |
| Money | Funding rounds, funding sources and partnerships |
| Space | Footprint requirements, physical residency only |
Company information, therapeutic area, differentiation, milestones, publications, IP status, financial information and footprint requirements come from JLABS. The non-confidential material list and the 12 to 18 month plan come from the JLABS resident application.
The milestone plan is where most applications go soft. It is an explicit field, so write it as dated gates with the money that pays for them.
✅ Good: Months 1 to 6, GLP tox in two species. Months 7 to 12, file the IND. Months 13 to 18, dose the first cohort. Funded through month 14 by the round that closed in March. Dated gates, and the reviewer can see who pays for them.
❌ Bad: Over the next 12 to 18 months we will advance our lead program toward the clinic and expand the team. No dates, no gate, and nothing that speaks to the financial solvency the screen asks about.
Physical residency or virtual membership: choose before you open the form
The two models solve different problems, and the application asks you to pick.
| Physical residency | Virtual membership | |
|---|---|---|
| Built for | Companies needing lab or office space | Startups not needing physical lab or office space |
| Extra application field | Footprint requirements | None published |
| Availability | Varies by site across 11 locations | Offered virtually |
Model definitions come from JLABS; the 11 locations globally and virtually, with availability differing by site, come from Johnson & Johnson Innovation.
Two things are not published, so stop looking for them. The public application instructions do not state a universal incorporation country requirement, and they do not state a single residency duration. Both can vary by site and model, so ask the site team instead of assuming in your board deck.
JLABS by Johnson & Johnson acceptance rate: not published, and what is
There is no public acceptance rate, applicant count or general cohort size, so any percentage you read on an aggregator is unverified. The numbers JLABS does publish are outcome counts.
| Published figure | Number |
|---|---|
| Member companies and residents globally | More than 1,240 |
| Funding raised by residents and members, secured and contingent | More than $173 billion |
| Deals and partnerships between Johnson & Johnson and member companies | More than 530 |
| JLABS East North America member companies, current and alumni | More than 340 |
| East North America members led by first-time entrepreneurs | 58% |
The first three come from JLABS. The site level figures, collected in June 2026, come from JLABS East North America, which also reports more than $20 billion in secured and contingent financial and strategic relationships.
58% of JLABS East North America member companies are led by first-time entrepreneurs (JLABS East North America). If you were about to apologise for being a first-time founder in the application, do not.
JLABS by Johnson & Johnson deadline 2026: residency is open, QuickFire is dated
Residency and virtual membership have no published general deadline. The application is presented as an open apply now portal rather than a dated cohort window (JLABS), which means the timing question is your milestone plan, not a calendar.
QuickFire Challenges are a separate track with their own dates and their own money. The Expanding Access to Immunology Clinical Trials QuickFire Challenge offers award funding from a total pool of up to $350,000, and its September 18, 2026 deadline applies to that challenge only, not to residency or virtual membership (Johnson & Johnson Innovation).
Do not present a QuickFire award as standard JLABS residency funding. Check the specific challenge page for its own window, and keep wider program cycle dates in our deadline calendar.
When this matters for your raise
JLABS changes your burn and your credibility, not your cap table. A residency that holds bench costs down while you hit a dated milestone is a stronger story to a lead than an accelerator equity trade, so run it alongside a live process, not instead of one. Price the space against the biotech seed fundraise benchmarks you are underwriting to, compare the trade against accelerator terms and dilution, and stack non-dilutive sources by reading how to apply to SBIR grants alongside this one. If keeping that parallel investor list warm is eating the week your milestone plan needs, tools like Causo run the outreach while the committee reviews.
FAQ
How hard is it to get into JLABS by Johnson & Johnson? Unknown in numeric terms. JLABS publishes no acceptance rate, applicant count or general cohort size, so treat any percentage on a third-party listing as unverified. What it does publish is the screen itself: transformational science or technology, a significant unmet medical or market need, a strong team, financial solvency, and alignment with Johnson & Johnson strategic interests or adjacencies (JLABS).
Does JLABS by Johnson & Johnson take equity? The official material does not state that JLABS takes equity. It describes the model as no-strings-attached, allowing entrepreneurs to develop their science while retaining their intellectual property (JLABS), so residency does not hand Johnson & Johnson rights over your company. No equity is not the same as no cost, and the official pages do not publish a rate card, so ask the specific site for current fees and minimum term.
How much funding does JLABS by Johnson & Johnson provide? The official pages do not publish a general funding amount for residency or virtual membership. The residency page lists lab space, equipment, collaborative offices, industry connections, mentorship and funding opportunities without promising a grant or investment amount (JLABS). Award figures belong to the separate QuickFire Challenges, for example the Expanding Access to Immunology Clinical Trials QuickFire Challenge and its pool of up to $350,000 (Johnson & Johnson Innovation).
When is the JLABS by Johnson & Johnson application deadline? There is no published general deadline for residency or virtual membership; the application is presented as an open portal (JLABS). Individual QuickFire Challenges carry their own dates, such as the September 18, 2026 deadline on the Expanding Access to Immunology Clinical Trials QuickFire Challenge, which does not apply to residency (Johnson & Johnson Innovation).
Is JLABS by Johnson & Johnson worth it for founders? It is worth it if you need lab space and proximity to healthcare expertise without giving up equity, given that JLABS reports more than 1,240 member companies and residents globally and more than 530 deals and partnerships with Johnson & Johnson (JLABS). It is not worth it if you are counting on a Johnson & Johnson check or partnership, because the published material describes opportunities and connections rather than guarantees (JLABS). Budget the space as a cost line, not as a grant.
Run this raise inside Causo.
Match to the best-fit partner at 1,000+ funds, draft a hyper-specific email, and send from your own inbox, in one place.